Next Steps Unclear For Impax Following “Not Approvable” Letter On Vadova For Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is concerned that the name Vadova may cause medication errors caused by confusing the drug with other marketed forms of carbidopa/levodopa.
You may also be interested in...
GSK Seeks Re-Entry To Parkinson's Market In Deal With Impax
With no Parkinson's candidates in its pipeline, the pharma pays $11.5 million upfront for ex-U.S. rights to Phase III compound.
GSK Seeks Re-Entry To Parkinson's Market In Deal With Impax
With no Parkinson's candidates in its pipeline, the pharma pays $11.5 million upfront for ex-U.S. rights to Phase III compound.
Vadova Launch Uncertain Following “Not Approvable” Letter From FDA
Impax seeks a meeting with the agency after a negative review that included inspection of a contract laboratory.